基于DTP药房回访数据探讨利司扑兰相关药学服务价值

石再欢; 王芳婷; 郭芷君; 黄硕涵; 朱林蕙; 王喆元; 杜琼; 翟青

doi:10.6039/j.issn.1001-0408.2023.19.19

您当前的位置：

首页 >

文章列表页 >

基于DTP药房回访数据探讨利司扑兰相关药学服务价值

药师与药学服务 | 更新时间：2023-10-09

- 基于DTP药房回访数据探讨利司扑兰相关药学服务价值
- Study on the value of pharmaceutical service related to risdiplam based on follow-up data of DTP pharmacy
- 中国药房 2023年34卷第19期页码：2414-2418
- 作者机构：
  
  1.上药云健康益药药房（上海）有限公司，上海;200032
  2.佛山市顺德区和祐美和医院，广东佛山　528399
  3.复旦大学附属肿瘤医院药剂科，上海　200032
- 作者简介：
  
  药师。研究方向：药学。电话：021-32096606。 E-mail：shizaihuan@sphcchina.com
  主任药师，博士。研究方向：肿瘤药学。E-mail：zhaiqing63@126.com
- 基金信息：
  
  上海市抗癌协会“翱翔”计划项目(SACA-AX202110)
- DOI：10.6039/j.issn.1001-0408.2023.19.19
  中图分类号： R952
- 纸质出版日期：2023-10-15，
  
  收稿日期：2023-02-24，
  
  修回日期：2023-08-08，
扫描看全文
石再欢,王芳婷,郭芷君等.基于DTP药房回访数据探讨利司扑兰相关药学服务价值 ^Δ[J].中国药房,2023,34(19):2414-2418.

SHI Zaihuan,WANG Fangting,GUO Zhijun,et al.Study on the value of pharmaceutical service related to risdiplam based on follow-up data of DTP pharmacy[J].ZHONGGUO YAOFANG,2023,34(19):2414-2418.
石再欢,王芳婷,郭芷君等.基于DTP药房回访数据探讨利司扑兰相关药学服务价值 ^Δ[J].中国药房,2023,34(19):2414-2418. DOI： 10.6039/j.issn.1001-0408.2023.19.19.

SHI Zaihuan,WANG Fangting,GUO Zhijun,et al.Study on the value of pharmaceutical service related to risdiplam based on follow-up data of DTP pharmacy[J].ZHONGGUO YAOFANG,2023,34(19):2414-2418. DOI： 10.6039/j.issn.1001-0408.2023.19.19.

摘要

目的

探索直销患者（DTP）药房开展利司扑兰相关药学服务的价值。

方法

收集2021年5月－2023年1月在上药云健康益药药房（上海）有限公司购买并使用利司扑兰的脊髓性肌萎缩症（SMA）患者的随访数据，对患者用药情况、药物治疗效果、不良事件发生情况进行回顾性分析。

结果

DTP药房药师共审核处方42份，发现不合理处方7份（16.7%，7/42），经药师及时干预后纠正。随访过程中，药师对4例（9.5%，4/42）患者关于利司扑兰服药要求、用药后不良事件等用药咨询进行专业解答。2例1型SMA患者出现不良事件：其中1例表现为发热，1例表现为皮肤干燥、局部颜色变暗；两者为Ⅰ级毒性反应，一般无需临床治疗，但考虑发热患者长时间持续低热，药师建议就医对症处理。

结论

DTP药房药师开展罕见病SMA患者使用利司扑兰的随访管理有助于促进患者合理规范用药。

Abstract

OBJECTIVE

To explore the value of providing pharmaceutical service related to risdiplam in direct-to-patient （DTP） pharmacies.

METHODS

The follow-up data of spinal muscular atrophy （SMA） patients who purchased and used risdiplam from Shangyao Yunjiankang Yiyao Pharmacy （Shanghai） Co.， Ltd. from May 2021 to January 2023 were collected. The medication information， therapeutic efficacy and the occurrence of adverse events were retrospectively analyzed.

RESULTS

A total of 42 prescriptions were checked by pharmacists in the DTP pharmacies， and 7 prescriptions were found to be unreasonable （16.7%， 7/42）， which were corrected after the timely intervention. During the follow-up management， pharmacists replied to 4 patients （9.5%， 4/42） regarding medication consultation about medication requirements and adverse events. Two patients with type Ⅰ SMA experienced adverse events： one of them presented with fever and the other presented with skin dryness with darkening. Both of them were grade Ⅰ toxic reactions and generally did not require clinical treatment. Considering that the patient sustained low-grade fever for a long time， the pharmacist suggested symptomatic treatment under the guidance of the doctor.

CONCLUSIONS

Pharmacists in DTP pharmacies conducting follow-up management of risdiplam use for rare disease SMA patients can help promote rational， standardized medication for patients.

关键词

DTP药房药学服务脊髓性肌萎缩症利司扑兰罕见病

Keywords

pharmaceutical servicespinal muscular atrophyrisdiplamrare diseases

references

OGINO S，WILSON R B. Genetic testing and risk assessment for spinal muscular atrophy （SMA）[J]. Hum Genet，2002，111（6）：477-500.

SIVARAMAKRISHNAN M，MCCARTHY K D，CAMPAGNE S，et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers[J]. Nat Commun，2017，8（1）：1476.

胡骏，薛礼浚，邵蓉.美国专业药房研究及其对我国DTP药房的启示[J].卫生经济研究，2018（11）：31-34.

HU J，XUE L J，SHAO R. Research on American professional pharmacy and its enlightenment to China’s DTP pharmacy[J]. Health Econ Res，2018（11）：31-34.

中华医学会儿科学分会康复学组，中国康复医学会物理治疗专委会. 脊髓性肌萎缩症康复管理专家共识[J]. 中华儿科杂志，2022，60（9）：883-887.

Subspecialty Group of Rehabilitation of the Society of Pediatrics of Chinese Medical Association，Physical Therapy Committee of Chinese Association of Rehabilitation Medicine. Expert consensus on rehabilitation management of the spinal muscular atrophy[J]. Chin J Pediatr，2022，60（9）：883-887.

MASSON R，MAZURKIEWICZ-BEŁDZIŃSKA M，ROSE K，et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy （FIREFISH part 2）：secondary analyses from an open-label trial[J]. Lancet Neurol，2022，21（12）：1110-1119.

MERCURI E，DECONINCK N，MAZZONE E S，et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy （SUNFISH part 2）：a phase 3，double-blind，randomised，placebo-controlled trial[J]. Lancet Neurol，2022，21（1）：42-52.

FINKEL R S，MERCURI E，DARRAS B T，et al. Nusiner- sen versus sham control in infantile-onset spinal muscular atrophy[J]. N Engl J Med，2017，377（18）：1723-1732.

MERCURI E，DARRAS B T，CHIRIBOGA C A，et al. Nusinersen versus sham control in later-onset spinal mu- scular atrophy[J]. N Engl J Med，2018，378（7）：625-635.

POIRIER A，WEETALL M，HEINIG K，et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs[J]. Pharmacol Res Perspect，2018，6（6）：e00447.

KAKAZU J，WALKER N L，BABIN K C，et al. Risdiplam for the use of spinal muscular atrophy[J]. Orthop Rev，2021，13（2）：25579.

CHIRIBOGA C A. Pharmacotherapy for spinal muscular atrophy in babies and children：a review of approved and experimental therapies[J]. Paediatr Drugs，2022，24（6）：585-602.

OSMANOVIC A，SCHREIBER-KATZ O，PETRI S. Nusinersen wearing-off in adult 5q-spinal muscular atrophy patients[J]. Brain Sci，2021，11（3）：367.

DARRAS B T，FARRAR M A，MERCURI E，et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy （SMA） treated with nusinersen in seven clinical trials[J]. CNS Drugs，2019，33（9）：919-932.

CHIRIBOGA C A，BRUNO C，DUONG T，et al. Risdiplam in patients previously treated with other therapies for spinal muscular atrophy：an interim analysis from the JEWELFISH Study[J]. Neurol Ther，2023，12（2）：543-557.

GLANZMAN A M，MAZZONE E，MAIN M，et al. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders （CHOP INTEND）：test development and reliability[J]. Neuromuscul Disord，2010，20（3）：155-161.

MAZZONE E S，MAYHEW A，MONTES J，et al. Revised upper limb module for spinal muscular atrophy：development of a new module[J]. Muscle Nerve，2017，55（6）：869-874.

IANNACCONE S T，HYNAN L S，MORTON A，et al. The PedsQL in pediatric patients with spinal muscular atrophy：feasibility，reliability，and validity of the pediatric quality of life inventory generic core scales and neuromuscular module[J]. Neuromuscul Disord，2009，19（12）：805-812.

DANY A，BARBE C，RAPIN A，et al. Construction of a quality of life questionnaire for slowly progressive neuromuscular disease[J]. Qual Life Res，2015，24（11）：2615-2623.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

美国《孤儿药法案》建立与修订过程研究及对我国的启示

基于5种罕见病可负担性评价的我国罕见病保障机制研究

2010－2015年美国FDA批准上市的孤儿药研究